Clinical Trials

Inclusion Criteria:

• Histological or cytological diagnosis of a relevant tumor type as per the study protocol and not candidates for curative surgery or radiation therapy.
• Available tumor tissue (archival or newly obtained core or excisional biopsy).
• Adequate hematologic and end organ function as measured by laboratory screening panel in the 14 days prior to treatment.
• Life expectancy greater than 12 weeks.
• ECOG performance status of 0 to 1.
• Adequate contraception for women of childbearing potential.
• 6-month wash-out of prior anti-PD1/PDL-1 therapy.

Exclusion Criteria:

• Concurrent active malignancy.
• Major surgery within 4 weeks of treatment.
• Subjects with active, known or suspected autoimmune diseases.
• Prior treatment with CD137 agonists, anti-CTLA-4 and anti-TIGIT antibodies.
• History of any Grade 3 or 4 immune-related AE toxicity from prior immunotherapy that resulted in treatment discontinuation.
• History of immune-related adverse events that lead to discontinuation of anti-PD-1 or PDL-1 therapy.
• Active infections of HIV, hepatitis B, hepatitis C.
• Medical illness or abnormal laboratory finding that would, in the Study Investigator's judgement, increase the risk to the subject associated with participation in the study.
• Pregnancy in female subjects.